Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.

Willis BA, Andersen SW, Ayan-Oshodi M, James DE, Liffick E, Hillgren K, Guo Y, Monk SA.

J Clin Pharmacol. 2019 Aug 5. doi: 10.1002/jcph.1500. [Epub ahead of print]

PMID:
31378968
2.

Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.

Morse BL, Alberts JJ, Posada MM, Rehmel J, Kolur A, Tham LS, Loghin C, Hillgren KM, Hall SD, Dickinson GL.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 28. doi: 10.1002/psp4.12447. [Epub ahead of print]

3.

Hepatic Organic Anion Transporting Polypeptide-Mediated Clearance in the Beagle Dog: Assessing In Vitro-In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance.

Matsunaga N, Ufuk A, Morse BL, Bedwell DW, Bao J, Mohutsky MA, Hillgren KM, Hall SD, Houston JB, Galetin A.

Drug Metab Dispos. 2019 Mar;47(3):215-226. doi: 10.1124/dmd.118.084194. Epub 2018 Dec 28.

PMID:
30593544
4.

Post-translational modifications of transporters.

Czuba LC, Hillgren KM, Swaan PW.

Pharmacol Ther. 2018 Dec;192:88-99. doi: 10.1016/j.pharmthera.2018.06.013. Epub 2018 Jun 30. Review.

PMID:
29966598
5.

Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.

Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM.

Clin Transl Sci. 2017 Nov;10(6):509-519. doi: 10.1111/cts.12486. Epub 2017 Jul 27.

6.

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.

Pak YA, Long AJ, Annes WF, Witcher JW, Knadler MP, Ayan-Oshodi MA, Mitchell MI, Leese P, Hillgren KM.

Drug Metab Dispos. 2017 Feb;45(2):137-144. doi: 10.1124/dmd.116.071118. Epub 2016 Nov 28.

7.

Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.

Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM.

Drug Metab Dispos. 2015 Mar;43(3):325-34. doi: 10.1124/dmd.114.059618. Epub 2014 Dec 12.

PMID:
25504564
8.

Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity.

Xu D, Wu M, Nishimura S, Nishimura T, Michie SA, Zheng M, Yang Z, Yates AJ, Day JS, Hillgren KM, Takeda ST, Guan Y, Guo Y, Peltz G.

J Pharmacol Exp Ther. 2015 Feb;352(2):274-80. doi: 10.1124/jpet.114.220798. Epub 2014 Nov 25.

9.

Deciphering ADME genetic data using an automated haplotype approach.

Guo Y, Farmen MW, Jin Y, Lee HY, Penny MA, Hillgren KM, Fossceco SL.

Pharmacogenet Genomics. 2014 Jun;24(6):292-305. doi: 10.1097/FPC.0000000000000047.

PMID:
24797890
10.

International Transporter Consortium commentary on clinically important transporter polymorphisms.

Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):23-6. doi: 10.1038/clpt.2013.12.

PMID:
23778707
11.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

12.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

13.

Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):52-63. doi: 10.1038/clpt.2013.74. Epub 2013 Apr 8. Review.

14.

Highlights from the International Transporter Consortium second workshop.

Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM.

Clin Pharmacol Ther. 2012 Nov;92(5):553-6. doi: 10.1038/clpt.2012.126.

PMID:
23085880
15.

[Widespread risk behavior among injecting drug users. Over 80 percent HCV-infected--7 percent have HIV, as demonstrated by the first baseline study].

Hillgren K, Sarkar K, Elofsson S, Britton S.

Lakartidningen. 2012 Jun 19-26;109(25):1221-5. Swedish. No abstract available.

PMID:
22838111
16.

Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden.

Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S.

Scand J Infect Dis. 2012 Nov;44(11):852-9. doi: 10.3109/00365548.2012.689847. Epub 2012 Jul 17.

PMID:
22803699
17.

Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics.

Zamek-Gliszczynski MJ, Day JS, Hillgren KM, Phillips DL.

Drug Metab Dispos. 2011 Oct;39(10):1794-800. doi: 10.1124/dmd.111.040162. Epub 2011 Jun 27.

PMID:
21708882
18.

Urinary ethyl glucuronide and ethyl sulfate testing for detection of recent drinking in an outpatient treatment program for alcohol and drug dependence.

Dahl H, Voltaire Carlsson A, Hillgren K, Helander A.

Alcohol Alcohol. 2011 May-Jun;46(3):278-82. doi: 10.1093/alcalc/agr009. Epub 2011 Feb 20.

PMID:
21339184
19.

Membrane transporters in drug development.

International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.

Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028. Review.

20.

Targeted disruption of peptide transporter Pept1 gene in mice significantly reduces dipeptide absorption in intestine.

Hu Y, Smith DE, Ma K, Jappar D, Thomas W, Hillgren KM.

Mol Pharm. 2008 Nov-Dec;5(6):1122-30.

21.

PhRMA white paper on ADME pharmacogenomics.

Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA.

J Clin Pharmacol. 2008 Jul;48(7):849-89. doi: 10.1177/0091270008319329. Epub 2008 Jun 4. Review.

PMID:
18524998
22.

Dynamin 2 regulates riboflavin endocytosis in human placental trophoblasts.

Foraker AB, Ray A, Da Silva TC, Bareford LM, Hillgren KM, Schmittgen TD, Swaan PW.

Mol Pharmacol. 2007 Sep;72(3):553-62. Epub 2007 Jun 12.

PMID:
17565002
23.

Comparison of human and monkey peptide transporters: PEPT1 and PEPT2.

Zhang EY, Emerick RM, Pak YA, Wrighton SA, Hillgren KM.

Mol Pharm. 2004 May-Jun;1(3):201-10.

PMID:
15981923
24.

Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586.

Zhang EY, Fu DJ, Pak YA, Stewart T, Mukhopadhyay N, Wrighton SA, Hillgren KM.

J Pharmacol Exp Ther. 2004 Aug;310(2):437-45. Epub 2004 Apr 9.

PMID:
15075386
25.

Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices.

Brown-Augsburger P, Yue XM, Lockridge JA, McSwiggen JA, Kamboj D, Hillgren KM.

J Pharm Biomed Anal. 2004 Jan 27;34(1):129-39.

PMID:
14738927
26.

Enhanced transepithelial transport of peptides by conjugation to cholic acid.

Swaan PW, Hillgren KM, Szoka FC Jr, Oie S.

Bioconjug Chem. 1997 Jul-Aug;8(4):520-5.

PMID:
9258450
27.

In vitro systems for studying intestinal drug absorption.

Hillgren KM, Kato A, Borchardt RT.

Med Res Rev. 1995 Mar;15(2):83-109. Review. No abstract available.

PMID:
7537838
28.

A new side-by-side diffusion cell for studying transport across epithelial cell monolayers.

Hidalgo IJ, Grass GM, Hillgren KM, Borchardt RT.

In Vitro Cell Dev Biol. 1992 Sep-Oct;28A(9-10):578-80. No abstract available.

PMID:
1429356
29.

Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus.

Hidalgo IJ, Hillgren KM, Grass GM, Borchardt RT.

Pharm Res. 1991 Feb;8(2):222-7.

PMID:
2023871

Supplemental Content

Loading ...
Support Center